Zobrazeno 1 - 10
of 870
pro vyhledávání: '"PIERFRANCO CONTE"'
Autor:
Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Gennari, Antonio Llombart, Miguel Martìn, Francesca Poggio, Aleix Prat, Fabio Puglisi, Cristina Saura
Publikováno v:
Breast, Vol 76, Iss , Pp 103742- (2024)
Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clini
Externí odkaz:
https://doaj.org/article/3fd5c1f752464c7f896a88384ff626ee
Autor:
Błażej Cieślik, Justyna Mazurek, Adam Wrzeciono, Lorenza Maistrello, Joanna Szczepańska-Gieracha, Pierfranco Conte, Pawel Kiper
Publikováno v:
npj Digital Medicine, Vol 6, Iss 1, Pp 1-10 (2023)
Abstract Technological advancements facilitate feedback adaptation in rehabilitation through virtual reality (VR) exergaming, serious gaming, wearables, and telerehabilitation for older adults fall prevention. Although studies have evaluated these te
Externí odkaz:
https://doaj.org/article/1d467be3721e470b83f6bdeb9ea6ff89
Autor:
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D’amico, Pierfranco Conte, Valentina Guarneri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1
Externí odkaz:
https://doaj.org/article/7d4d7386cfd94d75b1c2b14b831939b0
Autor:
Alessandra Buja, Giulia Pasello, Marco Schiavon, Giuseppe De Luca, Michele Rivera, Claudia Cozzolino, Anna De Polo, Manuela Scioni, Alberto Bortolami, Vincenzo Baldo, PierFranco Conte
Publikováno v:
Thoracic Cancer, Vol 13, Iss 19, Pp 2692-2698 (2022)
Abstract Background The monoclonal antibody durvalumab, an immune‐checkpoint inhibitor (ICI) antiprogrammed death ligand 1 (PD‐L1), is available for unresectable stage III NSCLC patients as consolidation therapy following induction chemoradiother
Externí odkaz:
https://doaj.org/article/102383d1d02341d0b308b7f98ec702cc
Autor:
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies rep
Externí odkaz:
https://doaj.org/article/b2d164b6afd24d32a7d34c45e4f0a7df
Autor:
Giovanna Garufi, Luisa Carbognin, Isabella Sperduti, Federica Miglietta, Maria Vittoria Dieci, Roberta Mazzeo, Armando Orlandi, Lorenzo Gerratana, Antonella Palazzo, Alessandra Fabi, Ida Paris, Antonio Franco, Gianluca Franceschini, Elena Fiorio, Sara Pilotto, Valentina Guarneri, Fabio Puglisi, Pierfranco Conte, Michele Milella, Giovanni Scambia, Giampaolo Tortora, Emilio Bria
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Given the low chance of response to neoadjuvant chemotherapy (NACT) in luminal breast cancer (LBC), the identification of predictive factors of pathological complete response (pCR) represents a challenge. A multicenter retrospective analy
Externí odkaz:
https://doaj.org/article/4c9a968a947b4e3ab35fb2655d5e106c
Autor:
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by includin
Externí odkaz:
https://doaj.org/article/474a667807c24ccf94e82782dbe6af54
Autor:
Valentina Guarneri, Fara Bras..-Maristany, Maria Vittoria Dieci, Gaia Griguolo, Laia Par.., Mercedes Mar.ín-Aguilera, Federica Miglietta, Michele Bottosso, Carlo Alberto Giorgi, Paula Blasco, Oleguer Castillo, Patricia Galv..n, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat
Publikováno v:
EBioMedicine, Vol 85, Iss , Pp 104320- (2022)
Summary: Background: HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene signatures (immune, proliferation, luminal differentiation and HER2 amplicon), includi
Externí odkaz:
https://doaj.org/article/7a7c9969d4c14817a9f13e36c3db43cc
Autor:
Maria Vittoria Dieci, Gaia Griguolo, Michele Bottosso, Vassilena Tsvetkova, Carlo Alberto Giorgi, Grazia Vernaci, Silvia Michieletto, Silvia Angelini, Alberto Marchet, Giulia Tasca, Elisa Genovesi, Enrico Cumerlato, Marcello Lo Mele, PierFranco Conte, Valentina Guarneri
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical outcomes according to ER levels in a monoinstitutional c
Externí odkaz:
https://doaj.org/article/a5d10581508547cdb6d83e4a415f9496
Autor:
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D’amico, Pierfranco Conte, Valentina Guarneri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/7ce7de244fa94f4e84d7b4647cdcd569